Gilead Misses Key Goal in NASH Liver Disease Trial, Shares Sink Gilead Misses Key Goal in NASH Liver Disease Trial, Shares Sink

Gilead Sciences Inc said on Monday that a late-stage study of a key experimental drug aimed at treating NASH, a progressive fatty liver disease, failed to meet its main goal, sending the company ' s shares down 4.6 percent in after-hours trading.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news